From Seekingalpha · Bret Jensen · · 50s
BioNTech SE Shifts Focus
BioNTech SE pivots from pandemic vaccines to oncology with $19B cash and 33 trials.
In brief
BioNTech SE pivots from pandemic vaccines to oncology with $19B cash and 33 trials. BioNTech SE is shifting from COVID-19 vaccines to oncology with $19B cash and 33 Phase 2/3 trials. Originally reported by Seekingalpha.
BioNTech SE
BioNTech SE is pivoting from a COVID-19 vaccine windfall to a robust oncology pipeline.
33 Phase 2/3 Trials
BioNTech SE has 33 Phase 2/3 trials in its oncology pipeline.
$19B Cash Reserves
BioNTech SE holds $19B in cash reserves for future oncology development.
Pumitamig Development
BioNTech SE's pumitamig, a PD-L1xVEGF bispecific, is in a crowded oncology space.
Pivotal Data Timeline
Pivotal data for pumitamig is expected post-2028 in the oncology space.
Profitability Timeline
BioNTech SE will not become profitable until 2031 despite strong cash reserves.
At a glance
BioNTech SE is shifting from COVID-19 vaccines to oncology with $19B cash and 33 Phase 2/3 trials.
